| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In CMML-developed Evi1-GFP;Kras-mutant mice, no GFP(Evi1)-positive leukemia cells were detected.
Even after 20-month observation, Evi1-GFP;ASXL-mutant knock-in mice looked healthy with no apparent signs of acute myeloid leukemia or myelodysplastic syndrome. ASXL-mutant knock-in BM cells showed a skewed differentiation to myeloid lineage. ASXL-mutant knock-in BM cells had 2.3-times higher hematopoietic colony formation capacity and higher replating capacity up to five times. These cells had a similar BM reconstituting capacity to wild type BM cells (eight-month observation). Retroviral CML induction to ASXL-mutant knock-in BM cells showed no acceleration of CML development, but recipients with IDH1-mutant transduced ASXL-mutant knock-in BM cells had leukemia development with 10-month duration while ASXL-wild counterparts showed no leukemia so far.
|
